|Trade names||Crestor, Rosulip, Zuvamor, others|
|Other names||Rosuvastatin calcium (USAN US)|
|By mouth (tablets)|
|Metabolism||Liver: CYP2C9 (major) and CYP2C19-mediated; ~10% metabolized|
|Metabolites||N-desmethyl rosuvastatin (major; 1/6–1/9 of rosuvastatin activity)|
|Elimination half-life||19 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||481.539 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Rosuvastatin, sold under the trade name Crestor among others, is a statin medication, used to prevent cardiovascular disease in those at high risk and treat abnormal lipids. It is recommended to be used together with dietary changes, exercise, and weight loss. It is taken by mouth.
Common side effects include abdominal pain, nausea, headaches, and muscle pains. Serious side effects may include rhabdomyolysis, liver problems, and diabetes. Use during pregnancy may harm the baby. Like all statins, rosuvastatin works by inhibiting HMG-CoA reductase, an enzyme found in the liver that plays a role in producing cholesterol.
Rosuvastatin was patented in 1991, and approved for medical use in the United States in 2003. It is available as a generic medication. In the United States, the wholesale cost per dose is less than US$0.15 as of 2018[update]. In the United Kingdom, it costs the NHS about £0.65 per dose as of 2018. In 2016, it was the 37th most prescribed medication in the United States, with more than 19 million prescriptions.
- 1 Medical uses
- 2 Side effects and contraindications
- 3 Drug interactions
- 4 Structure
- 5 Mechanism of action
- 6 Pharmacodynamics
- 7 Pharmacokinetics
- 8 Society and culture
- 9 References
- 10 External links
Effects on cholesterol levels
The effects of rosuvastatin on low-density lipoprotein (LDL) cholesterol are dose-related. Higher doses were more efficacious in improving the lipid profile of patients with hypercholesterolemia than milligram-equivalent doses of atorvastatin and milligram-equivalent or higher doses of simvastatin and pravastatin.
Meta-analysis showed that rosuvastatin is able to modestly increase levels of high-density lipoprotein (HDL) cholesterol as well, as with other statins. A 2014 Cochrane review determined there was good evidence for rosuvastatin lowering non-HDL levels linearly with dose. HDL increases by 7% with no dose effect noted.[medical citation needed]
Side effects and contraindications
Side effects are uncommon. The following side effects should be reported to the prescribing doctor if they persist or get worse:
- joint pain
- memory loss or forgetfulness
The following rare side effects are more serious. Like all statins, rosuvastatin can possibly cause myopathy, rhabdomyolysis. Stop taking rosuvastatin and contact the prescribing doctor if any of these occur:
- muscle pain, tenderness, or weakness
- lack of energy
- chest pain
- jaundice: yellowing of the skin or eyes
- dark colored, or foamy urine
- pain in the upper right part of the abdomen
- extreme tiredness
- unusual bleeding or bruising
- loss of appetite
- flu-like symptoms
- sore throat, chills, or other signs of infection
If any signs of an allergic reaction develop, contact an emergency medical service immediately:
- difficulty breathing or swallowing
- swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs
- numbness or tingling in fingers or toes
Rosuvastatin has multiple contraindications, conditions that warrant withholding treatment with rosuvastatin, including hypersensitivity to rosuvastatin or any component of the formulation, active liver disease, elevation of serum transaminases, pregnancy, or breastfeeding. Rosuvastatin must not be taken while pregnant as it can cause serious harm to the unborn baby. In the case of breastfeeding, it is unknown whether rosuvastatin is passed through breastmilk but, due to the potential of disrupting the infant's lipid metabolism, patients should not breast feed while on rosuvastatin.
The risk of myopathy may be increased in Asian Americans: "Because Asians appear to process the drug differently, half the standard dose can have the same cholesterol-lowering benefit in those patients, though a full dose could increase the risk of side-effects, a study by the drug's manufacturer, AstraZeneca, indicated." Therefore the lowest dose is recommended in Asians.
As with all statins, there is a concern of rhabdomyolysis, a severe undesired side effect. The U.S. Food and Drug Administration (FDA) has indicated that "it does not appear that the risk [of rhabdomyolysis] is greater with Crestor than with other marketed statins", but has mandated that a warning about this side-effect, as well as a kidney toxicity warning, be added to the product label.
- Coumarin anticoagulants ('blood thinners', e.g. warfarin) can affect the removal of rosuvastatin
- Ciclosporin, colchicine
- Drugs that may decrease the levels or activity of endogenous steroid hormones, e.g. cimetidine, ketoconazole, and spironolactone
- Additional medications for high cholesterol such as clofibrate, fenofibrate, gemfibrozil, and niacin (when taken in lipid-modifying doses of 1 g/day and above)
- Specific protease inhibitors including atazanavir (when taken with ritonavir), lopinavir/ritonavir and simeprevir
- Alcohol intake should be reduced while on rosuvastatin in order to decrease risk of developing liver damage
- Aluminum and magnesium hydroxide antacids should not be taken within two hours of taking rosuvastatin
- Coadministration of rosuvastatin with eluxadoline may increase the risk of rhabdomyolysis and myopathy:8
Rosuvastatin has structural similarities with most other synthetic statins, e.g., atorvastatin, cerivastatin and pitavastatin, but unlike other statins, rosuvastatin contains sulfur (in sulfonyl functional group).
Crestor is actually a calcium salt of rosuvastatin, i.e. rosuvastatin calcium, in which calcium replaces the hydrogen in the carboxylic acid group on the right of the skeletal formula at the top right of this page.
Mechanism of action
Putative beneficial effects of rosuvastatin therapy on chronic heart failure may be negated by increases in collagen turnover markers as well as a reduction in plasma coenzyme Q10 levels in patients with chronic heart failure.
In a Cochrane systematic review the dose-related magnitude of rosuvastatin on blood lipids was determined. Over the dose range of 1 to 80 mg/day strong linear dose‐related effects were found; total cholesterol was reduced by 22.1% to 44.8%, LDL cholesterol by 31.2% to 61.2%, non-HDL cholesterol by 28.9% to 56.7% and triglycerides by 14.4% to 26.6%. 
Absolute bioavailability of rosuvastatin is about 20% and Cmax is reached in 3 to 5 hours; administration with food did not affect the AUC according to the original sponsor submitted clinical study and as per product label. However, a subsequent clinical study has shown a marked reduction in rosuvastatin exposure when administered with food. It is 88% protein bound, mainly to albumin. Fraction absorbed of rosuvastatin is frequently misquoted in the literature as approximately 0.5 (50%) due to a miscalculated hepatic extraction ratio in the original submission package subsequently corrected by the FDA reviewer. It is likely that closer to 0.25 (25%) of the administered dose is absorbed.
Rosuvastatin is metabolized mainly by CYP2C9 and not extensively metabolized; approximately 10% is recovered as metabolite N-desmethyl rosuvastatin. It is excreted in feces (90%) primarily and the elimination half-life is approximately 19 hours.
Society and culture
Indications and regulation
Rosuvastatin is approved in the United States for the treatment of high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia), and/or triglycerides (hypertriglyceridemia). In February 2010, rosuvastatin was approved by the FDA for the primary prevention of cardiovascular events.
Patent protection and generic versions
The main patent protecting rosuvastatin (RE37,314 — due to expire in 2016) was challenged as being an improper reissue of an earlier patent. This challenge was rejected in 2010, confirming protection until 2016.
The drug was billed as a "super-statin" during its clinical development; the claim was that it offers high potency and improved cholesterol reduction compared to rivals in the class. The main competitors to rosuvastatin are atorvastatin and simvastatin. However, people can also combine ezetimibe with either simvastatin or atorvastatin and other agents on their own, for somewhat similar augmented response rates. As of 2006[update] some published information for comparing rosuvastatin, atorvastatin, and ezetimibe/simvastatin results is available, but many of the relevant studies are still[when?] in progress.
First launched in 2003, sales of rosuvastatin were $129 million and $908 million in 2003, and 2004, respectively, with a total patient treatment population of over four million by the end of 2004. Annual cost to the UK National Health Service (NHS) in 2018 for 5-40mg rosuvastatin daily was £24-40, compared to £10-20 for 20-80mg simvastatin.
In 2013, it was the fourth-highest selling drug in the United States, accounting for approx. $5.2 billion in sales.
Debate and criticisms
In October 2003, several months after its introduction in Europe, Richard Horton, the editor of the medical journal The Lancet, criticized the way Crestor had been introduced. "AstraZeneca's tactics in marketing its cholesterol-lowering drug, rosuvastatin, raise disturbing questions about how drugs enter clinical practice and what measures exist to protect patients from inadequately investigated medicines," according to his editorial. The Lancet's editorial position is that the data for Crestor's superiority rely too much on extrapolation from the lipid profile data (surrogate end-points) and too little on hard clinical end-points, which are available for other statins that had been on the market longer. The manufacturer responded by stating that few drugs had been tested so successfully on so many patients. In correspondence published in The Lancet, AstraZeneca's CEO Sir Tom McKillop called the editorial "flawed and incorrect" and slammed the journal for making "such an outrageous critique of a serious, well-studied medicine."
In 2004, the consumer interest organization Public Citizen filed a Citizen's Petition with the FDA, asking that Crestor be withdrawn from the US market. On 11 March 2005, the FDA issued a letter to Sidney M. Wolfe, M.D. of Public Citizen both denying the petition and providing an extensive detailed analysis of findings that demonstrated no basis for concerns about rosuvastatin compared with the other statins approved for marketing in the United States.
- Aggarwal, RK; Showkathali, R (June 2013). "Rosuvastatin calcium in acute coronary syndromes". Expert Opinion on Pharmacotherapy. 14 (9): 1215–1227. doi:10.1517/14656566.2013.789860. PMID 23574635.
- "Rosuvastatin Calcium Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists (AHFS). Retrieved 24 December 2018.
- "Crestor (rosuvastatin calcium) Tablets. Full Prescribing Information" (PDF). AstraZeneca. Retrieved 29 November 2016.
- Fischer, Janos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 473. ISBN 9783527607495.
- "NADAC as of 2018-12-19". Centers for Medicare and Medicaid Services (CMS). Retrieved 22 December 2018.
- British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 203. ISBN 9780857113382.
- "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.
- Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW (2003). "Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)". Am J Cardiol. 92 (2): 152–60. doi:10.1016/S0002-9149(03)00530-7. PMID 12860216.
- McTaggart F (August 2008). "Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit". Cardiovasc Drugs Ther. 22 (4): 321–38. doi:10.1007/s10557-008-6113-z. PMC 2493531. PMID 18553127.
- Adams, S. P.; Sekhon, S. S.; Wright, J. M. (November 2014). "Lipid-lowering efficacy of rosuvastatin". Cochrane Database Syst Rev. 11 (11): CD010254. doi:10.1002/14651858.CD010254.pub2. PMC 6463960. PMID 25415541.
- "Rosuvastatin". MedlinePlus. U.S. National Library of Medicine. 15 June 2012. Retrieved 1 December 2012.
- "Crestor". RxList. 14 November 2012. Retrieved 1 December 2012.
- "Rosuvastatin". LactMed. U.S. National Library of Medicine. Retrieved 1 December 2012.
- Alonso-Zaldivar, Ricardo (3 March 2005). "FDA Advisory Targets Asian Patients". Los Angeles Times.
- Wu HF, Hristeva N, Chang J, Liang X, Li R, Frassetto L, Benet LZ (September 2017). "Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions". J Pharm Sci. 106 (9): 2751–2757. doi:10.1016/j.xphs.2017.03.027. PMC 5675025. PMID 28385543.
- Lee VW, Chau TS, Leung VP, Lee KK, Tomlinson B (December 2009). "Clinical efficacy of rosuvastatin in lipid management in Chinese patients in Hong Kong". Chin. Med. J. 122 (23): 2814–9. PMID 20092783.
- Asian-Americans Among Groups More at Risk of Serious Muscle Damage (WebMD).
- "FDA Alert (03/2005) - Rosuvastatin Calcium (marketed as Crestor) Information". U.S. Food and Drug Administration (FDA). 14 March 2005. Archived from the original on 5 March 2005. Retrieved 20 March 2005. - This page is subject to change; the date reflects the last revision date.
- Sattar, N; Preiss, D; Murray, HM; Welsh, P; Buckley, BM; de Craen, AJ; Seshasai, SR; McMurray, JJ; Freeman, DJ; Jukema, JW; Macfarlane, PW; Packard, CJ; Stott, DJ; Westendorp, RG; Shepherd, J; Davis, BR; Pressel, SL; Marchioli, R; Marfisi, RM; Maggioni, AP; Tavazzi, L; Tognoni, G; Kjekshus, J; Pedersen, TR; Cook, TJ; Gotto, AM; Clearfield, MB; Downs, JR; Nakamura, H; Ohashi, Y; Mizuno, K; Ray, KK; Ford, I (27 February 2010). "Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials". Lancet. 375 (9716): 735–42. doi:10.1016/S0140-6736(09)61965-6. PMID 20167359.
- "FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs". Food and Drug Administration. 9 February 2019.
- "Viberzi (eluxadoline) Tablets, for Oral Use, CIV. Full Prescribing Information". Actavis Pharma, Inc. Retrieved 29 November 2016.
- Nissen SE, Nicholls SJ, Sipahi I, et al. (2006). "Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial" (PDF). JAMA. 295 (13): 1556–65. doi:10.1001/jama.295.13.jpc60002. PMID 16533939. Archived from the original (PDF) on 29 September 2007.
- Ashton E, Windebank E, Skiba M, et al. (January 2010). "Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study". Int J Cardiol. 146 (3): 404–7. doi:10.1016/j.ijcard.2009.12.028. PMID 20085851.
- Adams, Stephen P.; Sekhon, Sarpreet S.; Wright, James M. (21 November 2014). "Rosuvastatin for lowering lipids. Cochrane Database of Systematic Reviews". The Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd (11): CD010254. doi:10.1002/14651858.cd010254.pub2. PMC 6463960. PMID 25415541.
- Li, Yunxia; Jiang, Xuehua; Lan, Ke; Zhang, Ruoqi; Li, Xue; Jiang, Qian (1 October 2007). "Pharmacokinetic Properties of Rosuvastatin After Single-Dose, Oral Administration in Chinese Volunteers: A Randomized, Open-Label, Three-Way Crossover Study". Clinical Therapeutics. 29 (10): 2194–2203. doi:10.1016/j.clinthera.2007.10.005. ISSN 0149-2918. PMID 18042475.
- Bergman, Ebba; Lundahl, Anna; Fridblom, Patrik; Hedeland, Mikael; Bondesson, Ulf; Knutson, Lars; Lennernäs, Hans (1 December 2009). "Enterohepatic Disposition of Rosuvastatin in Pigs and the Impact of Concomitant Dosing with Cyclosporine and Gemfibrozil". Drug Metabolism and Disposition. 37 (12): 2349–2358. doi:10.1124/dmd.109.029363. ISSN 1521-009X. PMID 19773540.
- "Page 45 of FDA Drug Approval Package, Clinical Pharmacology Biopharmaceutics Review(s) (PDF)". Food and Drug Administration. 29 January 2004. Retrieved 22 June 2016.
- "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names (Rec. INN): List 45" (PDF). World Health Organization. 2001. p. 50. Retrieved 29 November 2016.
- "Core Data Sheet, Crestor Tablets" (PDF). AstraZeneca. June 17, 2003. Archived from the original (PDF) on May 8, 2005. Retrieved March 20, 2005. - NOTE: this is provider-oriented information and should not be used without the supervision of a physician.
- "FDA Approves New Drug for Lowering Cholesterol". Food and Drug Administration. 12 August 2003. Archived from the original on 7 February 2005. Retrieved 20 March 2005.
- "AstraZeneca's Crestor patent upheld;No generic competition until 2016".[dead link]
- "Crestor Patent Upheld By US Court" (Press release). AstraZeneca. 29 June 2010. Retrieved 25 April 2012.
- Berkrot, Bill; Hals, Tom (29 June 2010). "U.S. judge rules AstraZeneca Crestor patent valid". Reuters. Retrieved 25 April 2012.
- Starkey, Jonathan (1 July 2010). "AstraZeneca patent upheld". The News Journal. Wilmington, Delaware. Retrieved 25 April 2012. (subscription required)
- "FDA approves first generic Crestor". Food and Drug Administration. 29 April 2016. Retrieved 3 May 2016.
- "Mylan Launches Generic Crestor Tablets" (Press release). Mylan. July 2016.
- "COST COMPARISON CHARTS" (PDF). REGIONAL DRUG AND THERAPEUTICS CENTRE (NEWCASTLE). August 2018.
- "Top 100 Drugs for Q2 2013 by Sales". Retrieved 24 August 2013.
- Horton, Richard (25 October 2003). "The statin wars: why AstraZeneca must retreat". Lancet. 362 (9393): 1341. doi:10.1016/S0140-6736(03)14669-7. PMID 14585629.
McKillop T (1 November 2003). "The statin wars". Lancet. 362 (9394): 1498. doi:10.1016/S0140-6736(03)14698-3. PMID 14602449.
- "Docket No. 2004P-0113/CP1" (PDF). Food and Drug Administration.
- Rosuvastatin, U.S. National Library of Medicine Drug Information Portal